Roche to buy Seragon for up to $1.725 billion
Genentech to Buy Seragon Pharmaceuticals for up to $1.725 Billion
Genentech to Buy Seragon Pharma For up to $1.725 Billion
These quality funds with smaller asset bases have portfolios built around solid companies.
Large drugmakers are out of favor, but some good funds are banking on a rebound.
As incomes rise, emerging-markets consumers can afford more and better medications driving attractive growth in the pharmaceuticals sector, say the managers of Dodge & Cox International Stock.